

One-Year Follow-Up Result of TARGET I Clinical Endpoint Appraisal Committee Conference Held in Beijing

Shanghai, June 25, 2012 — — MicroPort Scientific Corporation announced that the primary endpoint results from prospective, multicenter, randomized clinical trials for assessing the safety and efficacy of Firehawk has been evaluated in the committee conference held in Beijing. Committee president, Professor Yong Huo, and other two committee members, Professor Weimin Wang and Professor Gao Wei, were invited. After analyzing data of endpoint results, including Major Adverse Cardiac Events (MACE) and related angiographic results, three professors made a rigorous, independent and authoritative appraisal and discussion, and the result will be submitted to related committee department for further data processing and analysis.

Aegis™-B Bifurcated Stent-Graft System Unveiled at the 1st Shanghai Jiaotong University Forum of Vascular Disease

Shanghai, July 6-8, 2012 — — MicroPort announced that its Aegis™-B Bifurcated Stent-Graft System had been unveiled at the 1st Shanghai Jiaotong University Forum of Vascular Disease which was co-organized by Vascular Center of Shanghai Jiaotong University School of Medicine, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong

Disclaimer: The content below is for communication purpose only. Our company and its affiliates do not guarantee to anybody that the information below is complete and up-to-date. Our company and its affiliates do not accept any responsibility for any decision made as a result of relying on the information contained herein.

University School of Medicine and other six hospitals.

On July 14, Aegis™-B had been used in the broadcasted live surgery at the 8th Yunnan Vascular Surgery Forum and it received high evaluation. Aegis™-B is scheduled to put into use on July 16 in Kunming 43 Hospital.

The 10th China Atrial Fibrillation Symposium Held in Dalian

Dalian, July 12-14, 2012 — — The 10th China Atrial Fibrillation Symposium was held in Dalian, on which Professor Ronghui Yu from Beijing An Zhen Hospital gave a report on the theme of Application of MicroPort Columbus™ 3D Electrophysiological Mapping System in Atrial Fibrillation Surgery. "Columbus™ system is the first 3D electrophysiological mapping system based on magnetic tracking technology in China," Professor Yu commented, "it is an innovative system that enables precise location of problem areas and reveals the bent condition of catheter. The system is revolutionary and there is no similar product on the market."

Suzhou Health Medical Obtained Business Operating License

Suzhou, June 26, 2012 — — MicroPort Scientific Corporation announced that Suzhou Health Medical Appliance Co., Ltd ("Suzhou Health") obtained Medical Device Business Operation License issued by

JSFDA (Jiangsu Food and Drug Administration) for 5 years valid period. The business scopes cover Group II and Group III, including 6846 implant materials and artificial organs. Suzhou Health is the first integrated medical device enterprise that has both manufacturing and business operating license in Zhang Jiagang, Jiangsu Province.

Suzhou Health Medical Appliance Co., Ltd is a wholly-owned subsidiary company of Suzhou Best Medical Instruments Co., Ltd. MicroPort Orthopedics Shanghai Co., Ltd., which is a wholly-owned subsidiary company of MicroPort Scientific Corporation, acquired 100% equity interest in Suzhou Best Medical Instruments Co., Ltd on September 9, 2011.

MicroPort Established a Wholly-Owned Subsidiary in Shanghai

MicroPort Scientific Corporation announced that MicroPort NeuroTech Co., Ltd., the sixth wholly-owned subsidiary of MicroPort, was established in Shanghai, and obtained Enterprise Entity Business License on May 16, 2012. The company primarily focuses on researching, manufacturing and marketing of medical devices in Central Nervous System Diseases, providing related services, including neuro-vascular intervention, neurological functional rehabilitation, neurosurgical equipments and so on. The company obeys to the

spirit of innovation, and dedicated to providing safe and reliable products, improving patients' life quality.

Appointment of Top Management

Shanghai, July 16, 2012 — — Approved by MicroPort's Board of Directors, Mr. Jonathan Chen formally assumed the position as Vice President in International Business & Investor Relations yesterday. Mr. Jonathan has 14 years of experience in life science industry including as Senior Vice President, Business Development & Financial Strategy at Angiotech Pharmaceuticals, Inc. based in Canada from 2005 to 2011 and Senior Vice President, Health Industry Investment at Credit Suisse First Boston. Mr. Jonathan received his undergraduate degree in Bioscience and Economics from Stanford University in 1997.

MicroPort New-Power Summer Camp 2012 Initiated

Shanghai, July 13, 2012 — — The Fifth MicroPort New-Power Summer Camp was initiated. 30 students, coming from Shanghai Jiaotong University, Xi'an Jiaotong University, Stanford University and other famous universities domestically and abroad, will spend four weeks in MicroPort Scientific Corporation in different departments including R&D, Registry, and Engineering. Students will be assigned with mentors who are excellent employees in MicroPort.

More Details on: www.microport.com.cn

Email: ir@microport.com

Tel (021) 38954600

Fax (021) 50801305